Commercial vial demand for SYFOVRE grew by 7% quarter ... The FDA approval and launch of CASGEVY, a gene therapy for treating sickle cell disease (SCD) and transfusion-dependent beta-thalassemia ...

Vertex is still in the early stages of the commercial launch of Casgevy, a one-time treatment for sickle cell disease and transfusion-dependent beta-thalassemia. The company now has more than 50 ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million. Bluebird makes three gene therapies: Zynteglo for beta thalassemia, Lyfgenia for sickle cell ...